Poland· PL-100351593
Lumark
A lutetium (177lu) oxodotreotide product containing lutetii chloridum [177lu], registered in Poland by I.D.B. Holland B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lutetium (177lu) oxodotreotide is registered in 11 of 19 countries.
Countries holding a registration under ATC V10XX04 (lutetium (177lu) oxodotreotide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Lutetium (177lu) oxodotreotide · ATC V10XX04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Lutetii chloridum [177Lu]
- Manufacturer
- I.D.B. Holland B.V.
- Country
- Poland (PL)
- ATC code
- V10XX04
- ATC class
- Lutetium (177Lu) oxodotreotide
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991371579
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under V10XX04
Lutetium (177lu) oxodotreotide, as other registers publish it.
- NetherlandsEndolucinBeta 40 GBq/mL, radiofarmaceutische precursor, oplossingITM Medical Isotopes GmbH
- DenmarkLutatheraNovartis Europharm Limited
- FinlandLutatheraNovartis Europharm Limited
- NorwayLutatheraNovartis Europharm Limited
- IcelandLutatheraNovartis Europharm Limited
- PolandLutatheraAdvanced Accelerator Applications
- CanadaLUTATHERANOVARTIS PHARMACEUTICALS CANADA INC
- CzechiaLUTATHERANovartis Europharm Limited, Dublin
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a10bc79b-4de9-46b9-b1d1-c5e91d2e42b2 GET /v1/drugs/a10bc79b-4de9-46b9-b1d1-c5e91d2e42b2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Prekursor radiofarmaceutyczny, roztwór",
"source": "urpl",
"strength": "80 GBq/ml",
"packaging": "05909991371579 ¦ Rpz ¦ EU/1/15/1013/001 ¦ 110316\n1 fiol. 0,1 5 ml",
"substance": "Lutetii (177Lu) Chloridum 80 GBq/ml",
"common_name": "Lutetii chloridum [177Lu]",
"pl_product_id": "100351593",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lutetium (177lu) oxodotreotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.